Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 168 participants.
Also called NCT05366101
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose supportive care
- Phase
- Phase 2/3
- Enrolled
- 168 participants
- Sponsor
- Registry
-
NCT05366101
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT05366101. Randomized; no masking; primary purpose supportive care. Start 2019-04-01 (actual); primary completion 2022-02-28 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy
- Acronym
- SILICOFCM
- Condition
- Hypertrophic Cardiomyopathy
- Intervention (Drug)
- Sacubitril/Valsartan
- Intervention (Behavioral)
- Lifestyle
- Lead sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
- Collaborator
- University Hospital Regensburg
- Collaborator
- Assistance Publique - Hôpitaux de Paris
- Collaborator
- Azienda Ospedaliero-Universitaria Careggi
- Collaborator
- Institute of Cardiovascular Diseases, Vojvodina
Record details
- Record id
cardio:ct-nct05366101- Content hash
804e3cad8d489098bef00ff4e37d9b43c574363f4246da39317937e103566b33